Skip to main content
. Author manuscript; available in PMC: 2012 Sep 14.
Published in final edited form as: Curr Cancer Ther Rev. 2011 Nov;7(4):248–260. doi: 10.2174/157339411797642605

Fig. (1). Transductional targeting of DCs with lentiviral vector.

Fig. (1)

In this scheme, DC transduction by specific surface targeting is shown as an example. Lentiviral particles are pseudotyped with a fusion protein together with an antibody that is specific for a particular surface protein present only in DC. These lentivectors can then specifically bind to the DC surface when administered in vivo (1). After binding, lentivectors fuse with the DC membrane and the core is incorporated and dismantled in the DC cytoplasm. The genome RNA is reversed-transcribed into a cDNA copy that integrates into the DC genome (2). From the integrated lentivector, transcription takes place leading to synthesis of TAAs, which are subsequently degraded (2). TAAs are processed into peptides and loaded in the MHC I compartment, together with DC activation by the transduction process itself. MHC I-peptide complexes are displayed on the DC surface and presented to TAA-specific CD8 T cells that differentiate in effector anti-tumour CTLs.